丁基硫
DL-BUTHIONINE-[S,R]-SULFOXIMINE
CAS: 5072-26-4
Molecular Formula: C8H18N2O3S
丁基硫 - Names and Identifiers
| Name | DL-BUTHIONINE-[S,R]-SULFOXIMINE |
| Synonyms | buthioninesulfoxamine buthioninesulfoximine DL-BUTHIONINE-SULFOXIMINE DL-BUTHIONINE (S,R)-SULPHOXIME DL-BUTHIONINE-[S,R]-SULFOXIMINE DL-BUTHIONINE (R,S)-SULFOXIMINE 2-amino-4-(s-butylsulfonimidoyl)butanoicacid 2-amino-4-(s-butylsulfonimidoyl)-butanoicaci (2R)-2-amino-4-(S-butylsulfonimidoyl)butanoic acid |
| CAS | 5072-26-4 |
| EINECS | 628-045-7 |
| InChI | InChI=1/C8H18N2O3S/c1-2-3-5-14(10,13)6-4-7(9)8(11)12/h7,10H,2-6,9H2,1H3,(H,11,12)/t7-,14?/m1/s1 |
丁基硫 - Physico-chemical Properties
| Molecular Formula | C8H18N2O3S |
| Molar Mass | 222.31 |
| Density | 1.29±0.1 g/cm3(Predicted) |
| Melting Point | 215°C (dec.)(lit.) |
| Boling Point | 382.3±52.0 °C(Predicted) |
| Flash Point | 185°C |
| Solubility | H2O: 50mg/mL, clear, colorless |
| Vapor Presure | 6.64E-07mmHg at 25°C |
| Appearance | Fluffy Powder |
| Color | White |
| Merck | 13,1520 |
| BRN | 2367136 |
| Storage Condition | 2-8°C |
| Refractive Index | 1.537 |
| Physical and Chemical Properties | Bioactive DL-Buthionine-Sulfoximine (BSO, DL-Buthionine-(S,R)-sulfoximine) is an inhibitor of glutathione (GSH) synthesis. |
| In vitro study | Buthionine sulfoximine is an analogs of methionine sulfoximine and inhibits gamma-glutamylcysteine synthetase about 20 times more effectively than prothionine sulfoximine and at least 100 times more effectively than methionine sulfoximine. |
| In vivo study | Treatment of mice bearing HT1080 and HT1080/DR4 xenografts with a continuous i.v infusion of nontoxic doses of D,L-Buthionine-(S,R)-sulfoximine (300 and 600 mg/kg/day) produce a 60% reduction of GSH plasma levels and greater than 95 % reduction in GSH tumor levels in both parental and multidrug-resistant tumors. |
丁基硫 - Risk and Safety
| Hazard Symbols | Xi - Irritant |
| Risk Codes | 36/37/38 - Irritating to eyes, respiratory system and skin. |
| Safety Description | S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S36 - Wear suitable protective clothing. |
| WGK Germany | 3 |
| RTECS | EK7713435 |
| FLUKA BRAND F CODES | 10 |
| HS Code | 29309090 |
丁基硫 - Upstream Downstream Industry
| Downstream Products | Ethyl 5-[3-(4,6-dimethoxy pyrimidyl-2-yl)ureido]methylpyrazolyl-4-carboxylic ester |
丁基硫 - Reference
| Reference Show more | 1. [IF=6.639] Xiao Zhang et al."ATP8B1 Knockdown Activated the Choline Metabolism Pathway and Induced High-Level Intracellular REDOX Homeostasis in Lung Squamous Cell Carcinoma."Cancers. 2022 Jan;14(3):835 |
丁基硫 - Nature
| storage conditions | 2-8°C |
| solubility | H2O: 50 mg/mL, clear, colorless |
| morphology | Fluffy Powder |
| color | White |
| Merck | 13,1520 |
| BRN | 2367136 |
Last Update：2024-04-10 22:29:15
丁基硫 - Uses and synthesis methods
in vitro study
Buthionine sulfoximine is an analogs of methionine sulfoximine and inhibits gamma-glutamylcysteine synthetase about 20 times more effectively than prothionine sulfoximine and at least 100 times more effectively than methionine sulfoximine.
in vivo studies
Treatment of mice bearing HT1080 and HT1080/DR4 xenografts with a continuous I .v infusion of nontoxic doses of D,L-Buthionine-(S,R)-sulfoximine (300 and 600 mg/kg/day) produce a 60% reduction of GSH plasma levels and greater than 95 % reduction in GSH tumor levels in both parental and multidrug-resistant tumors.
Last Update：2024-04-10 22:29:15
丁基硫 - Security information
| WGK Germany | 3 |
| RTECS number | EK7713435 |
| F | 10 |
| customs code | 29309090 |
Last Update：2024-04-10 22:29:15
丁基硫 - Reference Information
| biological activity | DL-Buthionine-Sulfoximine (BSO, DL-Buthionine-(S,R)-sulfoximine) is an inhibitor of glutathione (GSH) synthesis. |
| target | TargetValue GSH () |
| Target | Value |
| in vitro study | Buthionine sulfoximine is an analogs of methionine sulfoximine and inhibits gamma-glutamylcysteine synthetase about 20 times more effectively than prothionine sulfoximine and at least 100 times more effectively than methionine sulfoximine. |
| in vivo study | Treatment of mice bearing HT1080 and HT1080/DR4 xenografts with a continuous I. v infusion of nontoxic dos of D,L-Buthionine-(S,R)-sulfoximine (300 and 600 mg/kg/day) produce a 60% reduction of GSH plasma levels and greater than 95% reduction in GSH tumour levels in both parental and multidrug-resistant tumors. |
Last Update：2024-04-09 21:11:58
Supplier List
Product Name: DL-Buthionine-[S,R]-Sulfoximine Visit Supplier Webpage Request for quotation
CAS: 5072-26-4
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
CAS: 5072-26-4
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Product Name: DL-Buthionine-[S,R]-Sulfoximine Visit Supplier Webpage Request for quotation
CAS: 5072-26-4
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
CAS: 5072-26-4
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History
Downstream Products for 丁基硫